Xiao Wang

发表

Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial

Amber C. Donahue, X. Mu, R. Motzer, 2020, Nature Medicine.

Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial

Amber C. Donahue, X. Mu, R. Motzer, 2020, Nature Medicine.

Biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A+Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).

X. Mu, J. Larkin, R. Motzer, 2019, Journal of Clinical Oncology.